Vivacelle Bio, a biopharmaceutical company focused on developing treatments for shock and trauma, will be participating in BIO Partnering @ JPM Week 2025, taking place in San Francisco from January 13-16. The company plans to present its clinical development strategy and recent achievements to potential investors and partners during the event.
VBI-S for Hypovolemic Septic Shock
Vivacelle Bio's lead product, VBI-S, is currently in Phase 3 development for the treatment of hypovolemic septic shock. This life-threatening condition, which impacts millions worldwide, is characterized by dangerously low blood pressure and multiple organ failure. VBI-S is based on a patented phospholipid nanoparticle technology designed to redistribute nitric oxide, aiming to restore blood pressure and improve organ function.
Promising Phase 2 Results
In a Phase 2 trial, VBI-S demonstrated 100% efficacy in elevating blood pressure in hypovolemic septic shock patients who had not responded to other therapies. The treatment also markedly improved organ dysfunction in these patients, suggesting a significant clinical benefit. These results warrant further investigation in the ongoing Phase 3 trial.
Financial Backing and Future Plans
Vivacelle Bio has received financial support from both venture capital and government entities, including the US Department of Defense and the National Institutes of Health. The Phase 3 study of VBI-S is funded by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) program via the Medical Technology Enterprise Consortium (MTEC). The company's participation in BIO Partnering @ JPM Week 2025 represents an opportunity to secure further investment and partnerships to advance the development and commercialization of VBI-S.
